Botulinumtoxin A as a Treatment for Myalgia and Myofacial Pain in Patient With Temporomandibulardisorders

PHASE3RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Temporomandibular Disorder
Interventions
DRUG

5U/0,1 ml Botulinum toxin A

Botox® 100 U (AbbVie) will be dissolved in 2 milliliters of room-temperature sterile isotonic saline, resulting in a solution concentration of 5 U/0.1 mL. Each patient will receive a total dose of 50 U, administered bilaterally into the masseter and temporalis muscles.

DRUG

10U/0,1 ml Botulinum toxin A

Botox® 100 U (AbbVie) will be dissolved in 1 milliliters of room-temperature sterile isotonic saline, resulting in a solution concentration of 10 U/0.1 mL. Each patient will receive a total dose of 100 U, administered bilaterally into the masseter and temporalis muscles.

Trial Locations (1)

11324

RECRUITING

Eastman institute Folktandvården Region Stockholm, Stockholm

All Listed Sponsors
lead

Region Stockholm

OTHER_GOV